Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wagner, 2010, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD004064.pub3
Jung, 2002, Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model, Eur J Cancer, 38, 1133, 10.1016/S0959-8049(02)00013-8
Kim, 2009, The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer, Gut Liver, 3, 88, 10.5009/gnl.2009.3.2.88
Lieto, 2008, Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients, Ann Surg Oncol, 15, 69, 10.1245/s10434-007-9596-0
Song, 2002, Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer, World J Gastroenterol, 8, 591, 10.3748/wjg.v8.i4.591
Cabuk, 2007, Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival, Oncology, 72, 111, 10.1159/000111118
Juttner, 2006, Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma, J Clin Oncol, 24, 228, 10.1200/JCO.2004.00.3467
Murukesh, 2010, Biomarkers of angiogenesis and their role in the development of VEGF inhibitors, Br J Cancer, 102, 8, 10.1038/sj.bjc.6605483
Oh, 2008, Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer, BMC Cancer, 8, 123, 10.1186/1471-2407-8-123
Okines, 2011, Targeting angiogenesis in esophagogastric adenocarcinoma, Oncologist, 16, 844, 10.1634/theoncologist.2010-0387
Suzuki, 2010, Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer, BMC Cancer, 10, 659, 10.1186/1471-2407-10-659
Zhao, 2006, Microvessel density is a prognostic marker of human gastric cancer, World J Gastroenterol, 12, 7598, 10.3748/wjg.v12.i47.7598
Spratlin, 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 28, 780, 10.1200/JCO.2009.23.7537
Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205
Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365
DeMets, 1982, Asymmetric group sequential boundaries for monitoring clinical trials, Biometrika, 69, 661, 10.1093/biomet/69.3.661
Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139
Kang, 2012, Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone, J Clin Oncol, 30, 1513, 10.1200/JCO.2011.39.4585
Ford H, Marshall A, Wadsley J, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. 10th Annual Gastrointestinal Cancer Symposium; San Francisco, CA; Jan 24–26, 2013. LBA4.
Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002
Ohtsu, 2011, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study, J Clin Oncol, 29, 3968, 10.1200/JCO.2011.36.2236
Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X
Blumenschein, 2012, Targeting the hepatocyte growth factor-cMET axis in cancer therapy, J Clin Oncol, 30, 3287, 10.1200/JCO.2011.40.3774
Li, 2011, Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45, Cancer, 117, 3135, 10.1002/cncr.25893
Paterson, 2013, A systematic approach to therapeutic target selection in oesophago-gastric cancer, Gut, 62, 1415, 10.1136/gutjnl-2012-302039
Seto, 2009, Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer, Mol Carcinog, 48, 703, 10.1002/mc.20516
Song, 2011, Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer, PloS One, 6, e17687, 10.1371/journal.pone.0017687